Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) will report earnings before markets open on Thursday, May 2nd. Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.
Here is your Cheat Sheet to Teva Pharmaceutical Industries Limited Earnings:
Earnings Expectations: Analysts expect earnings of $1.10 per share on revenues of $4.85 billion. Currently, the company’s P/E ratio stands at 17.00.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $1.22 to a profit $1.21. For the current year, the average estimate is a profit of $5.05, which is worse than the estimate ninety days ago.
Here’s how Teva Pharmaceutical Industries Limited has been performing on an annual basis:
|Revenue ($) in millions||11,080||13,900||16,120||18,310||20,320|
|Diluted EPS ($)||0.78||2.23||3.67||3.09||2.25|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||5,676||5,102||4,994||4,972||5,249|
|Diluted EPS ($)||0.5724||0.97||0.99||-0.09||0.3682|
Teva Pharmaceutical Industries Limited has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)